Comparison of intrauterine transfusion techniques in hemolytic disease of the fetus and newborn

被引:0
|
作者
van't Oever, R. M. [1 ,2 ,3 ]
van Duijn, V. M. [1 ]
Slaghekke, F. [1 ]
Haak, M. C. [1 ]
de Winter, D. P. [2 ,3 ,4 ]
Lopriore, E. [4 ]
de Haas, M. [2 ,3 ,5 ]
Le Cessie, S. [6 ,7 ]
Verweij, E. J. T. [1 ]
机构
[1] Leiden Univ, Dept Obstet, Div Fetal therapy, Med Ctr, Leiden, Netherlands
[2] Sanquin Res, Translat Immunohematol, Amsterdam, Netherlands
[3] Amsterdam UMC, Landsteiner Lab, Amsterdam, Netherlands
[4] Leiden Univ, Willem Alexander Childrens Hosp, Dept Pediat, Div Neonatol,Med Ctr, Leiden, Netherlands
[5] Leiden Univ, Med Ctr, Dept Hematol, Leiden, Netherlands
[6] Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands
[7] Leiden Univ, Med Ctr, Dept Biomed Data Sci, Leiden, Netherlands
关键词
anemia; blood transfusion; erythroblastosis; fetal therapies; HDFN; intrauterine blood transfusion; RED-CELL ALLOIMMUNIZATION; FETAL; MANAGEMENT; HEMORRHAGE; ANEMIA;
D O I
10.1002/uog.29201
中图分类号
O42 [声学];
学科分类号
070206 ; 082403 ;
摘要
Objectives: Intrauterine transfusions (IUTs) are the cornerstone in treatment for hemolytic disease of the fetus and newborn (HDFN). It has been suggested that a non-vascular intraperitoneal blood transfusion used in conjunction with an intravascular IUT can slow the decrease in fetal hemoglobin (Hb) levels, potentially extending the interval between transfusions. Our aim was to evaluate the rate of decline in Hb levels and the interval between transfusions using different IUT techniques, including intrahepatic transfusions with and without intraperitoneal transfusion, and transplacental transfusion at the site of the placental cord insertion. Methods: We conducted a retrospective cohort study at the Leiden University Medical Center, the national referral center for HDFN, between January 2006 and December 2022. All cases that underwent intrahepatic (with and without intraperitoneal transfusion) and placental cord insertion IUTs during the study period were included. The primary outcome was the decline in Hb levels per week, measured by comparing the Hb level immediately after the IUT with the Hb level before the subsequent IUT or birth. The primary outcome was analyzed using generalized estimating equations with and without adjustment for confounders. Results: We included 309 fetuses that received a total of 791 IUTs, of which 151 were intrahepatic-only transfusions, 273 were intrahepatic + intraperitoneal transfusions and 367 were placental cord insertion transfusions. We found an adjusted mean difference in the decline in Hb levels of 0.48 (95% CI, 0.29-0.66) g/dL/week between the group that underwent intrahepatic-only transfusion and the group that underwent intrahepatic + intraperitoneal transfusion (P < 0.001). The adjusted mean difference between the intrahepatic-only IUT group and the placental cord insertion IUT group was 0.49 (95% CI, 0.05-0.94) g/dL/week (P = 0.030). The median interval to the next IUT for the total cohort was 21 (interquartile range (IQR), 18-28) days. Similarly, in the intrahepatic-only and placental cord insertion IUT groups, the median interval to the next IUT was 21 (IQR, 19-28) and 21 (IQR, 15-26) days, respectively. In the intrahepatic + intraperitoneal transfusion group, the median interval was slightly higher (26 (IQR, 21-28) days). Conclusion: Decline in Hb levels was slower when using intrahepatic + intraperitoneal transfusion compared with other IUT techniques and seemed to prolong the interval between IUT procedures. The potential clinical advantages of the intrahepatic + intraperitoneal transfusion technique need to be weighed against the increased complexity and extended duration of the procedure on an individual basis. (c) 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
收藏
页码:589 / 596
页数:8
相关论文
共 50 条
  • [1] Postponing Early intrauterine Transfusion with Intravenous immunoglobulin Treatment; the PETIT study on severe hemolytic disease of the fetus and newborn
    Zwiers, Carolien
    van der Bom, Johanna G.
    van Kamp, Inge L.
    van Geloven, Nan
    Lopriore, Enrico
    Smoleniec, John
    Devlieger, Roland
    Sim, Pauline E.
    Ledingham, Marie Anne
    Tiblad, Eleonor
    Moise, Kenneth J., Jr.
    Gloning, Karl-Philip
    Kilby, Mark D.
    Overton, Timothy G.
    Jorgensen, Ditte S.
    Schou, Katrine V.
    Paek, Bettina
    Walker, Martin
    Parry, Emma
    Oepkes, Dick
    de Haas, Masja
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2018, 219 (03) : 291.e1 - 291.e9
  • [2] Long-term neurodevelopmental outcome after intrauterine transfusion for hemolytic disease of the fetus/newborn: the LOTUS study
    Lindenburg, Irene T.
    Smits-Wintjens, Vivianne E.
    van Klink, Jeanine M.
    Verduin, Esther
    van Kamp, Inge L.
    Walther, Frans J.
    Schonewille, Henk
    Doxiadis, Ilias I.
    Kanhai, Humphrey H.
    van Lith, Jan M.
    van Zwet, Erik W.
    Oepkes, Dick
    Brand, Anneke
    Lopriore, Enrico
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2012, 206 (02)
  • [3] Intrauterine transfusion and non-invasive treatment options for hemolytic disease of the fetus and newborn - review on current management and outcome
    Zwiers, Carolien
    van Kamp, Inge
    Oepkes, Dick
    Lopriore, Enrico
    EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (04) : 337 - 344
  • [4] Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn
    Delaney, Meghan
    Matthews, Dana C.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2015, : 146 - 151
  • [5] Early and Severe Hemolytic Disease of the Fetus and Newborn
    Mayer, Beate
    Weichert, Alexander
    TRANSFUSIONSMEDIZIN, 2020, 10 (02) : 89 - 93
  • [6] Neonatal outcomes following intrauterine transfusion for hemolytic disease of the fetus and newborn: a twenty-year service review
    Blyth, Ursula
    Larsson, Martina
    Baird, Aimi
    Waring, Gareth
    Athiraman, Naveen
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2022, 35 (25) : 10220 - 10225
  • [7] Monitoring and management of hemolytic disease of the fetus and newborn based on an international expert Delphi consensus
    Mustafa, Hiba J.
    Sambatur, Enaja, V
    Shamshirsaz, Alireza A.
    Johnson, Sonia
    Moise Jr, Kenneth J.
    Baschat, Ahmet A.
    Verweij, E. J. T.
    Javinani, Ali
    Kilby, Mark D.
    Lopriore, Enrico
    Rose, Rebecca
    Devlieger, Roland
    Snowise, Saul
    Sachs, Ulrich J.
    Khalil, Asma
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2025, 232 (03) : 280 - 300
  • [8] Hemolytic disease of the fetus and newborn and Rhesus alloimmunization in Latin American countries: a scoping review
    Correa Junior, Mario Dias
    Espino y Sosa, Salvador
    Fernandes, Milene
    do Carmo, Lais
    de Oliveira, Renato Watanabe
    Kanevsky, Gabriela
    BMC PREGNANCY AND CHILDBIRTH, 2024, 24 (01)
  • [9] Management and Treatment Outcomes of Hemolytic Disease of the Fetus and Newborn (HDFN)-A Retrospective Cohort Study
    Drozdowska-Szymczak, Agnieszka
    Lukawska, Sabina
    Mazanowska, Natalia
    Ludwin, Artur
    Krajewski, Pawel
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (16)
  • [10] School performance and behavioral functioning in children after intrauterine transfusions for hemolytic disease of the fetus and newborn
    Ree, I. M. C. D.
    van 't Oever, R. M.
    Jansen, L.
    Lopriore, E.
    de Haas, M.
    van Klink, J. M. M.
    EARLY HUMAN DEVELOPMENT, 2021, 157